An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Open accessThe DOI matches its Crossref record; 324 of the 325 references it cites were found in a registry or an index.
Abstract
This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, all patients originally gathered from hospital register using ICD-10 codes were meticulously re-assessed and re-classified using the year 2011 criteria, and the cases representing some other type of ILDs were excluded [14].”
From Comparison of disease progression subgroups in idiopathic pulmonary fibrosis (2019) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ILD still has a poor prognosis and the highest mortality rate during lung transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interstitial lung disease (ILD) remains an important indication for lung transplantation, and the number of patients with this disease is increasing.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), characterized histopathologically and/or radiologically with a usual interstitial pneumonia (UIP) pattern, is the most common adult form of interstitial pneumonia of unknown origin [1].”
From Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature (2014) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median survival time for patients with IPF is 2 to 3 years from diagnosis and the 5-year survival rate ranges between 30% and 50% [1,5-7].”
From Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature (2014) · cites this paper as [1]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Interpretative strategies for lung function tests
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., Coates, A., van der Grinten, C. P. M., Gustafsson, P., Hankinson, J., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035205 · Cited by 5,945
Fleischner Society: Glossary of Terms for Thoracic Imaging
Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008) · Radiology · doi:10.1148/radiol.2462070712 · Cited by 4,198
Self-citation(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Standardisation of the measurement of lung volumes
Wanger, J., Clausen, J. L., Coates, A., Pedersen, O. F., Brusasco, V., Burgos, F., Casaburi, R., Crapo, R., Enright, P., van der Grinten, C. P. M., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035005 · Cited by 2,768
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Standardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
Research works printed but not linked: 9
- Cochrane Handbook for Systematic Reviews of Interventions 5.0.2. Oxford: The Cochrane Collaboration, 2009. [online] 2009. [accessed 20 June 2010]; Available from: http://www.cochrane.org/resources/handbook/.
- Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004;126:438–446. [DOI] [PubMed] [Google Scholar]
- 2005, J Gastrointest Surg, 1053
- Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the UK. Thorax 2000;55:143–146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517–525. [DOI] [PubMed] [Google Scholar]
- Kondo A, Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: Harasawa M, Fukuchi Y, Morinari H, editors. Interstitial pneumonia of unknown etiology. Tokyo: University of Tokyo Press; 1989. pp. 33–42.
- Flaherty KR, Colby TV, Toews GB, Travis WD, Flint A, Gay SE, Strawderman RL III, Jain A, Lynch JP III, Martinez FJ. Differential presence of fibroblastic foci in UIP patients with or without conntective tissue disease. Am J Respir Crit Care Med 2001;163:A983. [Google Scholar]
- Molina-Molina M, Badia JR, Marin-Arguedas A, Xaubet A, Santos MJ, Nicolas JM, Ferrer M, Torres A. Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit: a study of 20 cases. Med Clin (Barc) 2003;121:63–67. [DOI] [PubMed] [Google Scholar]
- Pitsiou G, Ioannis Trigonis I, Tsiata E, Kontou P, Manolakoglou N, Stanopoulos I, Mavrofridis E, Argyropoulou P. Outcome of patients with pulmonary fibrosis admitted to the ICU for acute respiratory failure. Eur Respir J Suppl 2006;28:E650. [Google Scholar]
Cited by
Items 1,001–1,060 of 1,060
The Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Tzouvelekis, A., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 72
Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors
Sack, C., & Raghu, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.01699-2018 · Cited by 72
Self-citationKorfei, M., von der Beck, D., Henneke, I., Markart, P., Ruppert, C., Mahavadi, P., Ghanim, B., Klepetko, W., Fink, L., Meiners, S., et al. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.04.033 · Cited by 72
Schrom, E., Huber, M., Aneja, M., Dohmen, C., Emrich, D., Geiger, J., Hasenpusch, G., Herrmann-Janson, A., Kretzschmann, V., Mykhailyk, O., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.006 · Cited by 69
Ahangari, F., Price, N. L., Malik, S., Chioccioli, M., Bärnthaler, T., Adams, T. S., Kim, J., Pradeep, S. P., Ding, S., Cosmos, C., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.158100 · Cited by 70
Lee, J., Arisi, I., Puxeddu, E., Mramba, L. K., Amicosante, M., Swaisgood, C. M., Pallante, M., Brantly, M. L., Sköld, C. M., & Saltini, C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194803 · Cited by 69
Hatipoglu, O. F., Uctepe, E., Opoku, G., Wake, H., Ikemura, K., Ohtsuki, T., Inagaki, J., Gunduz, M., Gunduz, E., Watanabe, S., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111633 · Cited by 67
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Montesi, S. B., Mathai, S. K., Brenner, L. N., Gorshkova, I. A., Berdyshev, E. V., Tager, A. M., & Shea, B. S. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-5 · Cited by 66
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0308-z · Cited by 65
Morisset, J., Vittinghoff, E., Lee, B. Y., Tonelli, R., Hu, X., Elicker, B. M., Ryu, J. H., Jones, K. D., Cerri, S., Manfredi, A., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.04.012 · Cited by 65
Self-citationRibeiro Neto, M. L., Jellis, C. L., Joyce, E., Callahan, T. D., Hachamovitch, R., & Culver, D. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201902-119cme · Cited by 63
Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis
Sokai, A., Handa, T., Tanizawa, K., Oga, T., Uno, K., Tsuruyama, T., Kubo, T., Ikezoe, K., Nakatsuka, Y., Tanimura, K., et al. (2015) · Respiratory Research · doi:10.1186/s12931-015-0280-9 · Cited by 64
Rathinasabapathy, A., Horowitz, A., Horton, K., Kumar, A., Gladson, S., Unger, T., Martinez, D., Bedse, G., West, J., Raizada, M. K., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00180 · Cited by 62
Lambers, C., Roth, M., Jaksch, P., Muraközy, G., Tamm, M., Klepetko, W., Ghanim, B., & Zhao, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19294-1 · Cited by 61
Spagnolo, P., Kreuter, M., Maher, T. M., Wuyts, W., Bonella, F., Corte, T. J., Kopf, S., Weycker, D., Kirchgaessler, K.-U., & Ryerson, C. J. (2018) · Respiration · doi:10.1159/000489668 · Cited by 61
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging
Piñeiro-Hermida, S., Autilio, C., Martínez, P., Bosch, F., Pérez-Gil, J., & Blasco, M. A. (2020) · Journal of Cell Biology · doi:10.1083/jcb.202002120 · Cited by 60
Enomoto, Y., Matsushima, S., Shibata, K., Aoshima, Y., Yagi, H., Meguro, S., Kawasaki, H., Kosugi, I., Fujisawa, T., Enomoto, N., et al. (2018) · Clinical Science · doi:10.1042/cs20180435 · Cited by 60
Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis
Sakamoto, S., Itoh, T., Muramatsu, Y., Satoh, K., Ishida, F., Sugino, K., Isobe, K., & Homma, S. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8498 · Cited by 59
Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.002 · Cited by 59
Self-citationPirfenidone for idiopathic pulmonary fibrosis
Bouros, D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60546-1 · Cited by 58
Self-citationIron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage?
Puxeddu, E., Comandini, A., Cavalli, F., Pezzuto, G., D'Ambrosio, C., Senis, L., Paci, M., Curradi, G., Sergiacomi, G. L., & Saltini, C. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.12.002 · Cited by 57
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compere, C., Maddens, S., Kirchgaessler, K.-U., Bartley, K., & Bondue, B. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000331 · Cited by 54
Lee, S. H., Park, J. S., Kim, S. Y., Kim, D. S., Kim, Y. W., Chung, M. P., Uh, S. T., Park, C. S., Park, S. W., Jeong, S. H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23073-3 · Cited by 50
Self-citationSystematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
Fleetwood, K., McCool, R., Glanville, J., Edwards, S. C., Gsteiger, S., Daigl, M., & Fisher, M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s5 · Cited by 49
The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis
Nishimoto, K., Fujisawa, T., Yoshimura, K., Enomoto, Y., Enomoto, N., Nakamura, Y., Inui, N., Sumikawa, H., Johkoh, T., Colby, T. V., et al. (2018) · Respirology · doi:10.1111/resp.13219 · Cited by 47
Self-citationEffect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W. (2019) · Respiratory Research · doi:10.1186/s12931-019-1021-2 · Cited by 43
Self-citationPrognostic Value of Serum Osteopontin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Gui, X., Qiu, X., Xie, M., Tian, Y., Min, C., Huang, M., Hongyan, W., Chen, T., Zhang, X., Chen, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/3424208 · Cited by 43
Gill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung
Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41
Sharp, C., Adamali, H. I., & Millar, A. B. (2017) · ERJ Open Research · doi:10.1183/23120541.00096-2016 · Cited by 41
Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Roach, K., Castells, E., Dixon, K., Mason, S., Elliott, G., Marshall, H., Poblocka, M., Macip, S., Richardson, M., Khalfaoui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679388 · Cited by 39
The role of precision medicine in interstitial lung disease
Maher, T. M., Nambiar, A. M., & Wells, A. U. (2022) · European Respiratory Journal · doi:10.1183/13993003.02146-2021 · Cited by 38
Self-citationUnderlying and immediate causes of death in patients with idiopathic pulmonary fibrosis
Kärkkäinen, M., Nurmi, H., Kettunen, H.-P., Selander, T., Purokivi, M., & Kaarteenaho, R. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0642-4 · Cited by 38
Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts
Sanders, Y. Y., Liu, H., Scruggs, A. M., Duncan, S. R., Huang, S. K., & Thannickal, V. J. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0034oc · Cited by 38
Hahn, A. D., Carey, K. J., Barton, G. P., Torres, L. A., Kammerman, J., Cadman, R. V., Lee, K. E., Schiebler, M. L., Sandbo, N., & Fain, S. B. (2022) · Radiology · doi:10.1148/radiol.211433 · Cited by 33
De Biasi, S., Cerri, S., Bianchini, E., Gibellini, L., Persiani, E., Montanari, G., Luppi, F., Carbonelli, C. M., Zucchi, L., Bocchino, M., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0515-0 · Cited by 28
Self-citationJo, H. E., Glaspole, I., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., Allan, H., et al. (2019) · Respirology · doi:10.1111/resp.13427 · Cited by 28
Maher, T. M., Schlecker, C., Luedtke, D., Bossert, S., Zoz, D. F., & Schultz, A. (2022) · ERJ Open Research · doi:10.1183/23120541.00240-2022 · Cited by 26
Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0126-7 · Cited by 25
Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
Kärkkäinen, M., Kettunen, H.-P., Nurmi, H., Selander, T., Purokivi, M., & Kaarteenaho, R. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0996-2 · Cited by 23
Akaike, K., Saruwatari, K., Oda, S., Shiraishi, S., Takahashi, H., Hamada, S., Iyama, S., Horio, Y., Tomita, Y., Saeki, S., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01584-x · Cited by 23
Isshiki, T., Sakamoto, S., Yamasaki, A., Shimizu, H., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106551 · Cited by 19
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Sivaraman, L., Gill, M., Nelson, D. M., & Chadwick, K. D. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115846 · Cited by 17
At the bedside: the emergence of group 2 innate lymphoid cells in human disease
Peebles, R. S. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3bt0814-383r · Cited by 17
Deep learning and the evaluation of pulmonary fibrosis
Levin, D. L. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30371-0 · Cited by 16
Sullivan, D. I., Jiang, M., Hinchie, A. M., Roth, M. G., Bahudhanapati, H., Nouraie, M., Liu, J., McDyer, J. F., Mallampalli, R. K., Zhang, Y., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.600626 · Cited by 16
He, X., Ji, J., Zheng, D., Luo, Z., Luo, L., & Guo, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1450798 · Cited by 15
Todd, J. L., Neely, M. L., Overton, R., Mulder, H., Roman, J., Lasky, J. A., de Andrade, J. A., Gulati, M., Huang, H., Leonard, T. B., et al. (2022) · Lung · doi:10.1007/s00408-021-00505-y · Cited by 14
Self-citationJapanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition
Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.02.014 · Cited by 12
Self-citationIkeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., et al. (2022) · Medicine · doi:10.1097/md.0000000000029232 · Cited by 11
Lee, J., & Song, J.-U. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e48 · Cited by 10
Indications for Lung Transplantation and Patient Selection
Son, J., & Shin, C. (2022) · Journal of Chest Surgery · doi:10.5090/jcs.22.057 · Cited by 10
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., et al. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231165912 · Cited by 8
Bouros, D., Daniil, Z., Papakosta, D., Antoniou, K. M., Markopoulou, K., Kolilekas, L., Konstantopoulos, G., Papiris, S., & on behalf of the INDULGE IPF Study Group (2018) · Respiration · doi:10.1159/000487244 · Cited by 7
Self-citationZhang, X.-L., Cao, Y., & Zheng, B. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02778-w · Cited by 7
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial
Maher, T. M., Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., Selman, M., Song, J. W., Ittrich, C., Diefenbach, C., Stowasser, S., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00335-2023 · Cited by 7
Self-citationMontero-Benitez, M. Z., Carmona-Llanos, A., Fernández-Jiménez, R., Román-Jobacho, A., Gómez-Millán, J., Modamio-Molina, J., Cabrera-Cesar, E., Vegas-Aguilar, I., Amaya-Campos, M. D. M., Tinahones, F. J., et al. (2025) · Cancers · doi:10.3390/cancers17193255 · Cited by 7
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., White, E. S., Ittrich, C., Diefenbach, C., Rohr, K. B., Selman, M., & Maher, T. M. (2024) · ERJ Open Research · doi:10.1183/23120541.00558-2023 · Cited by 6
Self-citation
Metadata
- Authors
- Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., Lynch, D. A., Ryu, J. H., Swigris, J. J., Wells, A. U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D. M., Johkoh, T., Kim, D. S., King, T. E., Kondoh, Y., Myers, J., Müller, N. L., Nicholson, A. G., Richeldi, L., Selman, M., Dudden, R. F., Griss, B. S., Protzko, S. L., & Schünemann, H. J.
- Affiliations
- University of Washington (US)
- University of California, San Francisco (US)
- Mater Misericordiae University Hospital (IE)
- Ludwig-Maximilians-Universität München (DE)
- Mayo Clinic (US)
- University of Michigan (US)
- Tulane University (US)
- University of Colorado Boulder (US)
- National Jewish Health (US)
- Royal Brompton Hospital (GB)
- Hospital Universitario de La Princesa (ES)
- University Hospital of Alexandroupolis (GR)
- Universidade de São Paulo (BR)
- Tohoku University (JP)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- The University of Osaka (JP)
- University of Ulsan (KR)
- University of Modena and Reggio Emilia (IT)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- ORCID
- Raghu, Ganesh
- Collard, Harold R.
- Colby, Thomas V.
- Lasky, Joseph A.
- Lynch, David A.
- Ryu, Jay H.
- Swigris, Jeffrey J.
- Wells, Athol U.
- Ancochea, Julio
- Bouros, Demosthenes
- Carvalho, Carlos
- Costabel, Ulrich
- Johkoh, Takeshi
- King, Talmadge E.
- Kondoh, Yasuhiro
- Myers, Jeffrey
- Nicholson, Andrew G.
- Richeldi, Luca
- Selman, Moisés
- Schünemann, Holger J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-03
- Volume
- 183
- Issue
- 6
- Pages
- 788-824
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC5450933
- OpenAlex
- W2167383172
- Cited by
- 7,186
- References
- 325
- Citations by year
- 2026: 187 · 2025: 307 · 2024: 436 · 2023: 432 · 2022: 522 · 2021: 640 · 2020: 607 · 2019: 596 · 2018: 607 · 2017: 605 · 2016: 569 · 2015: 531 · 2014: 426 · 2013: 370 · 2012: 256
- FWCI
- 304.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Heart, Lung, and Blood Institute (K23HL092227)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, diagnosis, management, natural history (disease), staging, prognosis, risk factors, treatment, disease surveillance, GRADE
- MeSH terms
- Europe, Humans, International Cooperation, Japan, Latin America, Societies, Medical, United States, Evidence-Based Medicine, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.